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Abstract: Arenaviruses include lethal human pathogens which pose serious public health 
threats. So far, no FDA approved vaccines are available against arenavirus infections, and 
therapeutic options are limited, making the identification of novel drug targets for the 
development of efficacious therapeutics an urgent need. Arenaviruses are comprised of two 
RNA genome segments and four proteins, the polymerase L, the envelope glycoprotein 
GP, the matrix protein Z, and the nucleoprotein NP. A crucial step in the arenavirus life-
cycle is the biosynthesis and maturation of the GP precursor (GPC) by cellular signal 
peptidases and the cellular enzyme Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease 
(S1P) yielding a tripartite mature GP complex formed by GP1/GP2 and a stable signal 
peptide (SSP). GPC cleavage by SKI-1/S1P is crucial for fusion competence and 
incorporation of mature GP into nascent budding virion particles. In a first part of our 
review, we cover basic aspects and newer developments in the biosynthesis of arenavirus 
GP and its molecular interaction with SKI-1/S1P. A second part will then highlight the 
potential of SKI-1/S1P-mediated processing of arenavirus GPC as a novel target for 
therapeutic intervention to combat human pathogenic arenaviruses.      
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1. Introduction 
 
1.1. Arenaviruses are important human pathogens  
 
Arenaviruses are world-wide distributed negative strand RNA viruses that include a number of 
important human pathogens. The prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) 
was discovered by Armstrong and Lille upon passage of infectious material derived from a fatal case 
of encephalitis during the 1933 outbreak in St Louis (USA) [1]. Independently and almost at the same 
time, Rivers and Scott were able to isolate the same virus from patients with manifestations of aseptic 
meningitis [2], while Traub established that asymptomatic healthy mice can be carriers of the virus 
isolated from a mouse colony at the Rockefeller Institute [3]. During the following 30 years, several 
other viruses sharing the same unique features of LCMV were discovered and described giving rise to 
a new family of virus named Arenaviridae. The “sandy” appearance of the viral particles in electron 
microscopy, due to the presence of host ribosomes, is at the origin of the family name, which has its 
roots in the Latin word “arena”, meaning sand. 
Currently, 22 species of arenaviruses, belonging to one singe genus, are recognized [4]. Based on 
serological, genetic and geographical data, arenaviruses are divided into two major subgroups: the Old 
World (OW) and the New World (NW) complex. The Old World lineage consists of the prototypic 
LCMV and other viruses endemic to the African continent, including Lassa (LASV), Mopeia (MOPV), 
Ippy, and Mobala (MOBV) viruses. The larger New World complex is further divided into three 
clades, A, B and C. Clade B is the most important in term of human disease, since it contains the major 
viruses causing hemorrhagic fevers (HF) in South America, i.e. Junín (JUNV), Machupo (MACV), 
Guanarito (GTOV) and Sabia (SABV) viruses but also other non-pathogenic viruses, like Tacaribe 
(TCRV) and Amapari virus (AMPV). The geographical distribution of the different viral species is 
intrinsically connected to the distribution of their natural hosts, and inherently the specific diseases 
associated to each virus follow a similar spatial distribution. 
Several arenaviruses are causative agents of severe viral hemorrhagic fevers (VHF) in humans 
which are among the most devastating human diseases [5]. Among these, LASV is a major concern 
due to its high prevalence in Western Africa, where it causes several hundred thousand cases of Lassa 
fever every year, associated with high levels of morbidity and mortality [6]. Likewise, VHFs are also 
associated with several arenaviruses endemic in the South American continent, including JUNV, 
MACV, GTOV, and SABV, which are etiological agents of severe VHF in Argentina, Venezuela, 
Bolivia, and Brazil, respectively [7,8]. Among these, JUNV raises most concern due to its seasonal 
epidemics of Argentine hemorrhagic fevers [9,10] and high prevalence in rural areas while MACV, 
GTOV and SABV cause only sporadic outbreaks. The viral hemorrhagic fevers caused by arenaviruses 
are characterized by a broad range of clinical signs and symptoms and the differential diagnosis based 
on early clinical symptoms is often difficult. After and incubation period of 1-2 weeks, arenavirus 
VHF patients develop fever, weakness and general malaise, including cough, severe headache, and 
sore throat. Gastrointestinal symptoms are usually present with nausea, diarrhea, and vomiting. 
Clinical complications such as pleural effusions, facial edema, neurological complications and 
bleeding from mucosal surfaces indicate a poor diagnosis. In severe cases, deterioration is rapid and at 
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terminal stage patients often succumb to shock, although the mild blood loss alone does not account 
for the death of the patient.  
The worldwide distributed LCMV is recognized as a neglected human pathogen of clinical 
significance. Being rarely fatal in immune-competent individuals causing only asymptomatic or mild, 
self-limited disease, it represents however a major risk to transplanted patients under immune-
suppressive treatment [11]. LCMV further poses a significant risk to the fetus and the newborn via 
vertical transmission from acutely infected mothers in utero or perinatally resulting in severe brain 
malformation including hydrocephalus, chorioretinitis and mental retardation [12]. Employees of 
rodent breeding facilities are also at risk due to the exposure to chronicle infected animals as illustrated 
by a recent study conducted by the CDC where a mice breeding facility in Indiana (USA) showed that 
20% of the mice had LCMV-reactive serum and 25% of the facility workers showed immunological 
evidence of recent LCMV exposure [13]. 
Of concern is also the fast emergence of new arenavirus associated with VHF syndromes. Recent 
examples are Chapare virus, discovered in Bolivia, which is closely related to other South American 
arenaviruses [14], and Lujo virus, identified during a nosocomial outbreak of VHF with high mortality 
in Zambia and South Africa in 2008 that caused the death of four out of five patients [15]. The 
discovery of this virus represents the first new HF-associated arenavirus to be isolated and identified in 
Africa in nearly 40 years. The continued emergence of previously unrecognized arenaviruses 
associated with fatal human disease in recent years suggests that many others could be identified in the 
future, raising serious concerns. Furthermore, increasing international air traffic coming from regions 
where arenavirus VHFs are endemic raises the fear of importation into non-endemic regions, putting 
local populations at risk. Indeed, since 1970, there have been several cases of Lassa fever imported 
into Europe or North America [16].  
 
1.2. Arenavirus life-cycle 
 
Arenavirus replication has been covered by excellent recent reviews [17,18] and only a short 
overview will be given here. All arenaviruses consist of a nucleocapsid surrounded by a membrane 
envelope and have a non-lytic life cycle restricted to the cytoplasm (Fig. 1A). Arenaviruses use an 
ambisense coding strategy and each genomic segment, L and S directs the synthesis of two 
polypeptides in opposite orientations, separated by a noncoding intergenic region (IGR) [19]. The S 
RNA encodes the nucleoprotein (NP; ca 63 kDa) and the viral glycoprotein precursor (GPC; ca 75 
kDa) that is post-translationally cleaved by a cellular enzyme into the mature virion glycoproteins 
(GPs) GP1(44 kDa) and GP2 (35 kDa) (Fig. 1B). Mature GPs form trimers [20].The L RNA encodes 
the viral RNA-dependent RNA polymerase (RdRp, or L polymerase; ca 200 kDa), and a small RING 
finger protein (Z; ca 11 kDa) [21] (Fig. 1C). This ambisense organization means that while the NP and 
L proteins are translated directly from the genomic complementary mRNA, the GPC and Z proteins 
are synthesized from the genomic sense mRNAs that are transcribed using the corresponding 
antigenome RNA (agRNA) species [21]. Since the genomic RNA of arenaviruses cannot serve directly 
as a template for translation, arenaviruses behave like true negative strand RNA viruses.  
The arenaviruses life cycle starts with its attachment to the host cell. As for most viruses this early 
step is mediated by the interaction of a viral attachment protein to host cell-receptor(s). In the case of 
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the prototypic LCMV, its broad cell tropism early suggested ubiquitous expression of conserved 
cellular receptor(s). In 1998, dystroglycan (DG) was identified as the first cellular receptor for LCMV 
and LASV [22] and subsequently for other OW arenaviruses and Clade C NW viruses [23]. In 
contrast, Clade B NW arenaviruses use transferrin receptor 1 (TfR1) as cellular receptor [24]. While 
pathogenic NW viruses like JUNV, MACV, GTOV, and SABV recognize human TfR1, non-
pathogenic Clade B viruses use murine TfR1 orthologues [25]. The cellular receptors of Clade A NW 
arenaviruses remain currently unknown. The entry pathway of OW and Clade C NW arenaviruses is 
unusual, being independent of known regulatory proteins associated with endocytosis. LASV and 
LCMV infections are independent of clathrin, caveolin, dynamin, and actin, and dependent on 
lysobisphosphatidic acid (LBPA), an unusual phospholipid that is involved in the formation of 
intraluminal vesicles of the multivesicular body of the late endosome [26]. We speculate that the virus 
bound to the receptor gets internalized hijacking a pathway normally associated with endocytosis and 
degradation of α-DG. Productive infection with LASV and LCMV requires the endosomal sorting 
complex required for transport (ESCRT) components Hrs, Tsg101, Vps22, and Vps24, as well as the 
ESCRT-associated ATPase Vps4 and Alix [26]. This peculiar pathway may represent a strategy of the 
virus to avoid recognition by the innate immunity sensors [27]. A very different scenario is found in 
the case of the NW arenaviruses that use TfR1 for internalization. Similarly to α-DG, TfR1 localizes 
on the cellular surface of the target cells but, differently from α-DG, TfR1 possesses ligands which are 
known to be internalized by the receptor [28]. A strong Type I IFN response is usually associated with 
early stage of JUNV infection [29]. 
Upon receptor binding, mediated by the membrane-distal GP1, arenaviruses are taken up by 
endocytosis and delivered to acidified endosomes [30]. There, a pH-dependent membrane fusion step, 
mediated by the GP2 portion of arenavirus GP, results in the release of the viral ribonucleoprotein 
(RNP) into the cytoplasm of the infected cell, followed by viral RNA genome replication and  gene 
transcription. Transcription by the viral L polymerase is initiated at promoters on each 5’end of the 
RNA segments, transcribing mRNA coding for the NP and L proteins. Transcription is terminated by 
structural motifs at the IGR downstream of the 3’end of each open reading frame [31]. Low levels of 
NP at the beginning of infection seem to prevent the virus polymerase from reading through the IGR, 
hence favoring transcription over replication. Subsequently, as NP accumulates, the viral polymerase 
shifts to a replicase mode and moves across the IGR, generating a full-length agRNAs which will serve 
as template for the synthesis of the GPC and Z mRNAs [32]. Complete viral genome is also amplified 
from the agRNA templates. Arenavirus infection induces discrete cytosolic structures for RNA 
replication [33].  
The formation and release of arenavirus infectious progeny requires that assembled viral RNPs 
associate at the cell surface with membranes that are enriched in mature viral GP. Virion assembly and 
budding is orchestrated by the bona fide matrix protein Z involving late (L) domain motifs (PTAP and 
PPPY) [34-36]. Incorporation of arenavirus GPs into virion particles depends on the interaction of GP 
with Z [37], which recruits components of the endosomal sorting complex required for transport 
(ESCRT), in particular the ESCRT-I component Tsg101, that is crucial for virion budding [34,35].  
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Figure 1. A) Schematic representation of arenavirus life cycle. Boxed regions refer to B) 
and C). For details, please see text. B) Biosynthesis of GPC in the ER with SSP cleavage 
by signal peptidase and maturation by the cellular protease SKI-1/S1P along the secretory 
pathway. The myristoylation modification and lysine 33 are also shown. Note that while 
LASV GP is cleaved early in the ER, LCMV GP is cleaved later in Golgi/TGN [38].  
C) Arenavirus virion structure showing the tripartite GP protein complex, the Zinc finger 
matrix protein (Z), the RNA dependent polymerase (L), the nucleoprotein (NP) and the 
negative single stranded ambisense RNA genome. 
 
 
 
2. The biosynthesis of the glycoprotein precursor 
 
The envelope glycoprotein of Arenaviruses is synthesized as a polypeptide composed of an N-
terminal stable signal peptide (SSP) and the SSP-containing GPC. Upon cleavage by cellular signal 
peptidases in the ER, GPC is further processed by the cellular proprotein convertase (PC) Subtilisin 
Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P) into the GP1 and GP2 subunits [39-41] (Fig. 1B). 
Post-translationally, the SSP acquires a myristoyl moiety at a Gly residue at position 2 [42] while the 
GP1/GP2 complex undergoes extensive N-glycosylation at multiple sites [43]. The interactions among 
the three subunits of the envelope glycoprotein, SSP, GP1, and GP2 are complex and not yet fully 
understood. 
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2.1. The signal peptide is not degraded and forms a stable tripartite complex with GP1/GP2 
 
The role of the stable signal peptide (SSP) of arenaviruses has been comprehensively reviewed by 
a recent excellent review [44]. The arenavirus SSP has several unique characteristics in addition to its 
conventional function of targeting the nascent GPC polypeptide into the ER. Processing of nascent 
GPC by cellular signal peptidases occurs co-translationally and results in an unusually long (58 amino 
acids) signal peptide which does not undergo immediate degradation, but has a half-life of > 6h [45-
47]. Standard signal peptides contain only one hydrophobic transmembrane domain but arenavirus SSP 
possess two hydrophobic regions separated by a hydrophilic loop containing a conserved positively 
charged Lys residue at position 33 (K33) [45]. Analysis of the JUNV SSP membrane topology 
revealed that both hydrophobic domains span the membrane with the N- and C-termini located in the 
cytosol and K33 facing the lumen/extracellular space [38]. SSP K33 is an important determinant for 
the pH-dependent fusion of the glycoprotein with the host cell membrane [48, 49]. The SSP associates 
with the GP2 subunit, involving a Zn-binding motif [42,50-53]. Interestingly, recently discovered 
small molecule inhibitors of arenavirus cell entry target the molecular interface between SSP and GP2 
[54], resulting in inhibition of pH-induced fusion. Lack of SSP myristoylation also affects fusion but 
not the formation of the SSP/GP1/GP2 complex [42]. The unusual arenavirus SSP is strictly required 
for proteolytic maturation of the GPC precursor [43,53]. Trans-complementation and interchanges 
among arenavirus GPC SSPs [55] are allowed but arenavirus SSP replacement with a generic signal 
peptide is not. In the case of JUNV GPC, the SSP was shown to be necessary for the GP to exit the ER 
by masking an ER-retention motif located on GP2 [53]. Lack of SSP would prevent the GP from being 
transported to the Golgi where SKI-1/S1P resides, thus averting maturation.  
 
2.2. Glycosylation of the GP1/GP2 complex  
 
N-linked glycosylation is an essential process to help correct folding and intracellular transport of 
viral envelope GPs [56]. Analysis of the potential sites of N-glycosylation on arenavirus GPs revealed 
4 conserved residues located on GP2 (with the exception of LCMV, DANV and LUJV), whereas the 
predicted sites on GP1 are multiple and show a lower degree conservation [43,57]. Recent studies 
showed that of the nine potential N-glycosylation sites of LCMV GPC, all the available sites were used 
on GP1 and two of three on GP2 [57]. All predicted N-glycosylation sites on LASV GPC (7 on GP1 
and 4 on GP2) are used [43]. Mutation of some N-glycosylation sites prevented proteolytic processing, 
whereas others were dispensable for GPC cleavage. The role of N-glycosylation for GPC maturation 
and transport is complex and may be different according to the arenavirus species. Eichler et al. 
demonstrated that uncleaved LASV GPC present on the cell-surface remain EndoH sensitive, 
indicating the presence of mannose glycans, but absence of hybrid and complex N-glycans. Based on 
this result, cleavage of LASV GPC into GP1 and GP2 was suggested to be required for complex N-
glycosylation upon exit from the ER [43]. Conversely, LCMV GPC cleavage was shown to occur after 
trimming of the mannose-rich N-glycans and their extension to complex N-linked sugars.  
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2.3. GPC is cleaved by the cellular protease SKI-1/S1P  
 
The majority of enveloped viruses shares a common mechanism of maturation based on the priming 
of their envelope GP precursors by host proteases in order to attain fusogenic properties [58-63]. 
Cleavage releases the fusion peptide, a hydrophobic stretch of 20-30 amino acids, which is able to act 
as an anchor in the target membrane, lowering the rupture tension of the lipid monolayer and 
promoting a negative curvature to ultimately allow joining the host-derived and virus membranes [64]. 
This strategy allows the envelope GP subunits to fold and oligomerize prior to assume, upon cleavage, 
a metastable conformation which undergoes drastic changes following receptor binding and/or drop of 
pH. The envelope precursor processing is also a mechanism to efficiently generate infectious particles 
since incorporation of mature envelope GPs is in general preferred over the uncleaved and fusion-
incompetent ones [40,65,66]. Relative tissue abundance of the specific enzyme responsible for the 
processing contributes to determine the tropism of the enveloped virus whose growth may therefore be 
limited to specific cells/organs.   
The arenavirus GPC is post-translationally cleaved at the highly conserved motif 
RX(hydrophobic)X↓, where X is any amino acid and hydrophobic is preferentially Leu (Fig. 2) [67]. 
In the absence of GP1, GP2 spontaneously forms a trimer, in which each subunit is folded in a 
“hairpin”-like postfusion conformation of class I viral fusion proteins [68, 69]. SKI-1/S1P is 
responsible for the cleavage of the GPCs of both OW [40] [39] and NW [41] arenaviruses. SKI-1/S1P 
belongs to the proprotein convertase (PC) family, which counts 9 members, so far, including 7 basic 
PCs (furin, PC1/3, PC2, PC4, PACE4, PC5/6, and PC7) and the self-inhibited proprotein convertase 
Subtilisin/Kexin type 9 (PCSK9). Differently from the other active members of PCs that cleave after 
clusters of (multi)basic motifs, the peculiar consensus sequence of SKI-1/S1P contains hydrophobic 
residues [70,71]. The protease is synthesized as an inactive zymogen that requires auto-processing of 
the N-terminal pro-domain at the B/B’ (RKVFRSLK) and C (RRLL) sites to attain full maturation 
[72]. In the cell, mature SKI-1/S1P localizes in the early Golgi, where the majority of its cellular 
substrates are cleaved, but also in the lysosomes and in the extracellular space, in a shed enzymatic 
form [71].  
The biological activities of SKI-1/S1P are numerous and affect essential cellular functions. Among 
the best characterized SKI-1/S1P substrates are the Sterol Regulating Element Binding Proteins 
(SREBPs), transcription factors activated via limited proteolysis to control cell lipid homeostasis 
[72,73]. In vivo studies suggest that blocking SKI-1/S1P activity may be an alternative approach to 
lower plasma cholesterol [74]. The SREBPs activation process, common to other transcription factors, 
is known as regulated intramembrane proteolysis (RIP) and involves translocation to the Golgi 
compartment upon specific stimuli and subsequent proteolytic cleavage. Member of the CREB/ATF 
family of transcription factors including ATF6 [75] CREBH, Luman, CREB3L4, CREB4, and OASIS, 
have been identified as SKI-1/S1P substrates, related to the unfolded protein response (UPR) [76]. 
Very few cellular examples of non-transcription factor proteins are known to be cleaved by SKI-1/S1P. 
Examples are N-acetylglucosamine-1-phosphotransferase, a key enzyme for the sorting of proteins into 
the lysosomal compartment [77], pro-brain derived neurotrophic factor (BDNF) [78] and repulsive 
guidance molecule (RGMa) [79]. SKI-1/S1P cleaves proBDNF within its pro-domain but the 
biological significance of this processing is not known. Similarly, RGMa processing by SKI-1/S1P 
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seems to be required although the cleavage sites have not yet been identified. The protease was also 
found to be crucial for normal bone and cartilage formation [80, 81], and mice coat pigmentation [82], 
but the substrates involved in these biological processes are still to be discovered. In mice, SKI-1/S1P 
K.O. shows a lethal phenotype with the embryos dying at an early developmental stage [83]. Even 
incomplete inhibition of SKI-1/S1P causes severe effects: homozygosity for the woodrat mutation, 
which shows partial loss of enzyme function, leads to hypersensitivity to dextran sodium sulfate-
induced colitis [84], and causes enhanced embryonic mortality [85]. 
Figure 2. Amino acid sequence aligment  of arenaviruses GPC residues surrounding  the 
cleavage site (indicated by arrow). Residues of mature GP1 are in light gray while residues 
of mature GP2 are in darkgray. The four amino acids of clevage site motif are in bold. The 
schematic cladogram indicates the phylogenetic relationships between the viral clades is 
shown on the right. The LCMV cl13 strain amino acid variant F260L is underlined. 
Accession numbers are in supplementary table 1. 
 
 
In contrast to cellular substrates of SKI-1/S1P that are processed in the median Golgi, LASV GPC 
is cleaved in the ER/cis-Golgi and LCMV GPC in a late Golgi compartment [39,71,86]. The way the 
virus is able to hijack active SKI-1/S1P in these specific subcellular compartments is not known. 
However, switching the LCMV GPC RRLA motif into RRLL present in LASV GPC re-direct the 
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cleavage of the latter from a late Golgi compartment to the ER/cis-Golgi. In contrast, a LASV GPC 
chimera carrying the LCMV “RRLA” motif, is not cleaved despite following normal sorting to the 
plasma membrane [86]. Thus, available evidence suggests that the specific amino acid sequence at the 
cleavage site may contribute to the processing at specific sub-cellular localizations. No clear 
information is currently available about the maturation of other arenavirus GPCs, although some 
evidences suggest JUNV GPC processing in the Golgi [87].  
A characteristic common to most arenavirus GPCs [67] (Fig. 2) is the striking resemblance of their 
processing sites to SKI-1/S1P auto-cleavage motifs: while African OW and NW clade B arenavirus 
GPCs mimic the C-auto-processing site “RRLL”, NW arenavirus GPCs resemble the B-auto-
processing site “RSLK”. The mimicry indicates convergent evolution towards a common maturation 
mechanism resembling SKI-1/S1P auto-processing, which is not evident in other cellular SKI-1/S1P 
substrates. The advantage may account for the virus’ ability to avoid interference with cellular 
functions in order to persist in the reservoir rodent host. Accordingly, the SKI-1/S1P-dependent 
activation of ATF6 is normally induced by LCMV GPC during acute infection. As soon as GPC 
expression is down-regulated during the transition from acute to persistent infection [88], the UPR 
response triggered by ATF6 disappears [89]. However, the reason behind the selective association 
“RRLL”-OW arenavirus and “RSLK”-NW arenavirus are currently unclear. 
Specific GPC residues surrounding the cleavage site were shown to influence maturation. An 
F259A point mutation at P7 position of LCMV GPC greatly impairs processing [39]. Analysis of 
peptides mimicking the cleavage site of LASV GPC revealed that cleavage efficiency may be 
negatively affected by the presence of a non-aromatic residue at P7 position, indicating the presence of 
an unusually large catalytic pocket able to accommodate residues distal from the actual processing site 
[70]. Indeed, in comparative studies, the YISRRLL sequence mimicking the cleavage site of LASV 
GPC is the best substrate to assess in vitro SKI-1/S1P enzymatic activity [77,78,90].  
The N-terminus of LASV GP2 contains two stretches of highly conserved hydrophobic amino 
acids. Alanine scanning of the N-terminal 260-266 and 276-298 sequences revealed that maturation of 
the envelope GPC does not occur in presence of single point mutations at positions 260, 261, 262, 280, 
284, 285, 286, 292, and 293, despite GPC folding and reaching the plasma membrane [91]. Indeed, 
GPC cleavage is not essential for transport to the plasma membrane, yet only the fully mature complex 
is found on budding particles [66, 72, 74]. A similar effect is observed in the case of the LASV GPC 
N-glycosylation mutants S367A and S375A, which are transported normally to the cell surface but fail 
to be cleaved [43]. LASV GP1 glycosylation at position 81, 91, 101, and 121 are required for 
proteolytic processing but not cell surface localization. In contrast, mutations that abolish normal 
glycosylation at positions 111, 169, and 226 are not crucial for the precursor maturation [43] . The data 
at hand thus suggest that SKI-1/S1P-mediated processing may require specific tertiary/quaternary 
structures of the GP1/GP2 complex that are disrupted by specific point mutations deletions.  
A large body of evidence indicate a crucial role of the cytoplasmic domains of viral envelope GPs 
in assembly, fusogenicity, and infectivity of enveloped viruses, including Newcastle disease virus [92] 
Measles virus [93], and HIV-1 [94]. Similar observations have been made with arenaviruses. Removal 
of the entire LCMV GP2 cytosolic tail as well as partial deletion of the three C-terminal amino acids 
RRK prevent maturation of GPC without interfering with its normal transport to the cell surface [65]. 
As similar role of amino acid residues in the cytoplasmic domain for GPC cleavage was observed by 
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Schlie et al. in the context of LASV GPC [95]. In arenaviruses, lack of cleavage has thus a drastic 
impact on infectious particles production since the process of GP incorporation into nascent virions 
discriminates processed over unprocessed GPC. 
 
2.4. Targeting GPC maturation is a promising strategy against arenavirus infection 
 
Similarly to other enveloped viruses, whose GPs are processed by PCs, such as HIV-1 and influenza 
virus, arenaviruses strictly rely on SKI-1/S1P for productive infection. In SKI-1/S1P-deficient cells, 
uncleaved GPCs are correctly transported to the plasma membrane but fail to be incorporated into 
budding particles, which remain “naked”, and lack infectivity [40,51,65]. Thus, GPC maturation 
represents an attractive drug target for complementary therapeutic intervention in addition to ribavirin. 
Over the past ten years, several SKI-1/S1P inhibitors have been synthesized and identified [67,70,96], 
but only few showed potential applications based on their cell-permeability, cytotoxicity and 
specificity. We [97] and others have shown that peptide- (dec-RRLL-cmk) or protein-(PDX-variants) 
[98] based SKI-1/S1P inhibitors efficiently blocks arenavirus cell-to-cell propagation. The on-target 
effect of dec-RRLL-cmk was demonstrated by using a recombinant LCMV bearing a furin-cleavable 
GPC, which was only slightly affected by the treatment [97]. More importantly, these investigations 
provided proof-of-concept that inhibition of GPC processing can contain the infection. Unfortunately, 
the use of the small molecule dec-RRLL-cmk was restricted due to its toxicity and follow-up studies in 
vivo were not feasible [99]. Rational design of SKI-1/S1P inhibitors is limited by the lack of structural 
information about the enzyme. As an alternative approach, Pfizer Inc. performed high-throughput 
small molecule screening using a homogeneous enzyme activity assay format based on purified soluble 
SKI-1/S1P that lead to the discovery of the aminopyrrolidineamide-based inhibitor PF-429242 with an 
in vitro IC50 in the nanomolar range [100]. The compound was potent in blocking SREBP-2 activation 
in vivo, significantly lowering plasma cholesterol levels [74]. PF-429242 is a potent inhibitor of cell-
to-cell propagation of OW arenaviruses via direct interference with the SKI-1/S1P-mediated GPC 
cleavage [101]. The on-target effect of PF-429242 was confirmed in vitro on synthetic peptides 
mimicking the cleavage site of the LASV GPC: processing of the LASV GPC derived Ac-IYISRRLL-
MCA peptide is inhibited by PF-429242 with an IC50 of 130 nM [99]. The small drug molecule 
appears to be effective against NW arenaviruses as well [99]. Combinatorial PF-429242 treatment with 
the well known broad anti-viral ribavirin shows a synergetic effect in vitro [99], suggesting that the 
administration of a SKI-1/S1P inhibitor may help to combat the infection.  
A hallmark of persistent infection is the down-regulation of GPC expression to almost undetectable 
levels with respect to the viral NP [102]. During this phase, infectious particles are still produced. It is 
conceivable that any perturbation of the GPC maturation may have drastic effects, as the envelope GP 
becomes the limiting factor for virus production and its inhibition cannot be compensated easily. 
Accordingly, in LCMV persistently infected cells the virus is rapidly cleared by PF-429242 treatment 
with apparently no emergence of escape variants [99]. Early studies in SKI-1/S1P-deficient cells 
showed that LCMV and JUNV can persist over long periods with a low probability of emergence of 
SKI-1/S1P independency before extinction [97]. In terms of drug development, this is of great 
importance because it suggests that the emergence of SKI-1/S1P-independent arenaviral variants is a 
rare event, further supporting the potential of SKI-1/S1P inhibitors as an anti-viral strategy. It is 
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currently unclear why arenaviruses cannot escape SKI-1/S1P deficiency. Possibly, SKI-1/S1P-
mediated GPC cleavage is crucial not only for the liberation of the N-terminal GP2 fusion peptide. 
Interestingly, addition of exogenous SKI-1/S1P is incapable of maturating GPC expressed at the 
surface of SKI-1/S1P null cells, suggesting that processing must occur in a specific sub-cellular 
compartment [86]. The relevance for SKI-1/S1P for productive arenavirus infection in vivo is further 
illustrated in mice homozygous for the hypomorphic Mbtps1 wrt allele (woodrat mutation), carrying a 
defective but still partially active SKI-1/S1P are resistant to LCMV infection [85].  
Given the importance of arenavirus envelope GPC processing for productive infection and its 
dependency on a protease involved in several crucial host functions, efforts have been made to 
understand how viral substrate and the enzyme interact, with the goal to eventually develop substrate-
specific drugs. Biochemical characterization of SKI-1/S1P-GPC interaction revealed that auto-
processing at the B/B’ sites of SKI-1/S1P is crucial for effective GPC maturation but not cellular 
SREBP-2 activation [86]. The exact reasons for the specific requirement of B/B’ autoprocessing for 
efficient cleavage of viral, but not cellular substrates are currently not known. However, this 
remarkable difference suggests that inhibitors of SKI-1/S1P autoprocessing may show some specificity 
for viral substrates with less of an effect on processing of cellular substrates. Moreover, the data at 
hand indicate that viral and cellular substrates of SKI-1/S1P are processed in distinct subcellular 
compartments. In uninfected cells, membrane-associated SKI-1/S1P is found predominantly in the 
early Golgi where cellular SKI-1/S1P substrates are cleaved [103]. In contrast, LASV GPC is cleaved 
early in the secretory pathway and LCMV GPC was shown to be processed in a late Golgi or post-
Golgi compartment [86]. The non-overlapping sub-cellular localization of viral and cellular substrates 
has been further supported by the finding that SKI-1/S1P mediated processing of ATF-6 is unaffected 
upon infection [89]. Targeting the protease in specific sub-cellular compartments may thus affect 
predominantly processing of viral GPCs. In this context, the recent reported protein inhibitor SKI-
1/S1P Spn4A.RRLL(r), a modified serpin with SKI-1/S1P specificity, coupled to HDEL ER-retention 
sequence [104] may act as a LASV specific inhibitor. Accordingly, Spn4A.RRLL(r) does inhibit SKI-
1/S1P in vitro without affecting the SREBP-2 pathway. As mentioned above, residues surrounding 
GPC processing site affect substrate-enzyme recognition. In particular, an aromatic amino acid at P7 
was found to be crucial for processing of both LASV [70] and LCMV GPC [39], making this region of 
the GPC an attractive anti-viral drug target given that the interference with P7-S7 interaction should 
not perturb the catalytic triad and thus general enzymatic activity. 
The envelope glycoprotein processing is a key step in arenavirus life-cycle. In vitro inhibition of 
SKI-1/S1P-mediated processing of GPC greatly limits virus cell-to-cell propagation, thus representing 
a promising antiviral strategy. In vivo evaluation of SKI-1/S1P inhibitors as antivirals, e.g. PF-429242, 
would be of great importance to understand the efficacy of interfering with normal GPC maturation on 
arenavirus infections. During drug treatment, dietary supplementation of cholesterol and other lipids 
may be taken into account to compensate for plasma cholesterol reduction, resulting from SREBPs 
inhibition. Novel substrate specific SKI-1/S1P inhibitors may be of great value to minimize side 
effects.   
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3. Role of the envelope glycoprotein on virus assembly and particle formation 
Viral infection induces a global reprogramming of cellular processes, including alterations the 
organization of intracellular membranes and organelles [105, 106]. Assembly of the viral components, 
and in particular GP, to form progeny infectious particle is still a process that remains for many aspects 
unknown. As introduced above, the driving force for arenaviruses budding is the matrix protein Z [34, 
35] which interacts via its late or RING domain with Tsg101, a member of the ESCRT machinery [34, 
36]. Myristoylation of Z is crucial for the correct matrix protein localization and therefore budding  
[107]. Z possesses per se budding properties and does not require any other viral protein to accomplish 
its function. However, the ability to produce infectious particles resides on the assembly of the four 
different viral proteins in a synchronized fashion. Thus, Z is required to interact with the 
SSP/GP1/GP2 complex that decorates the surface of the nascent particle. Confocal and biochemical 
analyses showed a direct LCMV and LASV GP1/GP2-Z interaction, dependent on the stable signal 
peptide of the GP complex [37]. Cells that express LASV GPC together with Z show a partial co-
localization in vesicle-like structures near the nucleus [108]. Sub-cellular localization of the envelope 
glycoprotein is not modified by the presence of Z [34]. Z myristoylation, but not on the Z late (L) or 
RING domain was shown to be responsible for the matrix protein binding to the envelope GP in OW 
arenaviruses [37]. However, disrupting the Z RING domain resulted in a drastic loss of TCRV and 
JUNV GP incorporation, suggesting some differences in the detailed molecular interactions underlying 
virion assembly in OW and NW viruses [109]. Further analyses are required to better understand the 
role of the GP complex in the virus budding events. The mechanisms underlying the selective 
incorporation of cleaved over uncleaved envelope GPs remain unclear and may involve different 
tertiary/quaternary structures of the mature SSP/GP1/GP2 complex in comparison to immature GPC 
[20]. Inhibition of virus assembly and budding is becoming more and more attractive as a drug target, 
opening the possibility to block egress of progeny virions from already infected cells. A detailed 
analysis of the molecular interactions underlying the recruitment of processed GP, Z, and the RNP into 
budding zones in infected cells will likely reveal promising drug targets for novel therapeutics to 
combat human arenavirus infection.   
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